Protara Therapeutics, Inc. (TARA) - What Are Analysts Saying About This Stock?

Key Points

• Analysts maintain a cautiously positive outlook: Protara Therapeutics has a consensus “Moderate Buy” rating from eight firms, with seven buys and one sell. The average 12-month price target is $26.25.
• Institutional ownership stands at 38.13%: Several hedge funds and institutional investors recently initiated or increased positions in the company.
• Shares face significant operating and market pressure: TARA opened at $2.32, near its 52-week low, and recently traded below its moving averages. The company also missed quarterly EPS expectations, reporting a loss of $0.36 per share versus the estimated $0.33 loss.

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $26.25.

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Protara Therapeutics in a research report on Thursday. Wall Street Zen raised Protara Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, September 5th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Protara Therapeutics in a report on Thursday.

Institutional Investors Weigh In On Protara Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Corient Private Wealth LP acquired a new position in shares of Protara Therapeutics during the second quarter worth approximately $41,000. Squarepoint Ops LLC acquired a new stake in Protara Therapeutics in the 2nd quarter valued at $69,000. The Manufacturers Life Insurance Company grew its position in Protara Therapeutics by 22.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 13,548 shares of the company's stock valued at $71,000 after purchasing an additional 2,464 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in Protara Therapeutics in the 2nd quarter valued at $113,000. Finally, WINTON GROUP Ltd increased its stake in Protara Therapeutics by 16.7% during the 2nd quarter. WINTON GROUP Ltd now owns 32,800 shares of the company's stock valued at $125,000 after purchasing an additional 4,700 shares in the last quarter. Institutional investors own 38.13% of the company's stock.

Protara Therapeutics Trading Down 3.3%

TARA opened at $2.32 on Friday. Protara Therapeutics has a 1-year low of $2.32 and a 1-year high of $7.82. The company has a market cap of $137.11 million, a P/E ratio of -1.72 and a beta of 1.47. The company has a fifty day moving average price of $3.49 and a two-hundred day moving average price of $4.17.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.03). On average, research analysts forecast that Protara Therapeutics will post -1.40 EPS for the current fiscal year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. The company's work centers on investigational treatments intended to address conditions with significant unmet medical needs.

Protara's lead product candidate is TARA-002, an investigational cell-based therapy derived from OK-432, a preparation based on a strain of Streptococcus pyogenes. The company is developing TARA-002 for non-muscle-invasive bladder cancer, a form of bladder cancer that has not invaded the bladder muscle, and for lymphatic malformations, rare abnormalities of the lymphatic system.

Protara conducts its research and clinical development activities primarily in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.